N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective [0.03%]
用于RNA药物的N-乙酰半乳糖胺递送系统专利分析透视 взгляд Patent透视 взгляд专利透视透视专利视角下的RNA疗法N-乙酰半乳糖胺递送系统专利分析透视
Hai-Long Zhang,Lansuo Wang
Hai-Long Zhang
Introduction: SiRNA molecules with a feature of good gene-silencing are critical for drug discovery and development based on RNA interference. GalNAc-RNA therapeutics is a rapid growing area in RNA therapeutics. ...
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders [0.03%]
下一代EGFR抑制剂：基于PROTAC的EGFR降解剂专利视角
Pengyun Li,Bingkun Li,Ning Yang et al.
Pengyun Li et al.
Introduction: Abnormal expression of epidermal growth factor receptor (EGFR) contributes to tumor development, especially in non-small cell lung cancer (NSCLC). Although multiple inhibitors have been developed to target d...
Weiwen Lu,Zhongbo Zhou,Neng Jiang et al.
Weiwen Lu et al.
Introduction: Type 2 diabetes (T2DM) and obesity present significant global health issues, requiring the development of long-lasting and highly effective pharmacotherapies. Although glucagon-like peptide-1 receptor agonis...
Linjie Li,Yu Guo,Yang Lu et al.
Linjie Li et al.
Introduction: Protein kinase B (Akt), an essential protein in the PI3K/Akt/mTOR signaling pathway, plays a crucial role in tumor progression. Over the past two years, different types of Akt modulators have continued to em...
G-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting [0.03%]
癌症相关基因启动子中的G-四链体：从识别到靶向治疗
Francesca Romano,Anna Di Porzio,Nunzia Iaccarino et al.
Francesca Romano et al.
Introduction: Guanine-rich DNA sequences can fold into four-stranded noncanonical secondary structures called G-quadruplexes (G4s) which are widely distributed in functional regions of the human genome, such as telomeres ...
Giorgia Gazzaroli,Andrea Angeli,Arianna Giacomini et al.
Giorgia Gazzaroli et al.
Introduction: The therapeutic targeting of the ubiquitin-proteasome pathway (UPP) through inhibitors of the 20S proteasome core proteolytic activities has revolutionized the treatment of hematological malignancies and is ...
Therapeutic treatment strategies for the management of onychomycosis: a patent perspective [0.03%]
从专利角度解析治疗甲真菌病的策略疗法
Snigdha Chakraborty,Sanshita,Inderbir Singh
Snigdha Chakraborty
Introduction: Onychomycosis, a multifactorial fungal infection of the nails, shows a global prevalence of about 5.5% and is responsible for 50% of all nail infections. To develop effective management strategies, it is nec...
Francesco Melfi,Simone Carradori,Noemi Mencarelli et al.
Francesco Melfi et al.
Introduction: Exploring the chemical diversity and molecular mechanisms of natural products continues to be an important research area for identifying novel promising therapeutic approaches for fighting cancer. This is a ...
An updated patent review of metallo-β-lactamase inhibitors (2020-2023) [0.03%]
2020-2023年金属β-内酰胺酶抑制剂专利回顾及分析
Elsa Denakpo,Thierry Naas,Bogdan I Iorga
Elsa Denakpo
Introduction: Metallo-β-lactamases (MBLs) are enzymes produced by bacteria that confer resistance to most β-lactam antibiotics, including carbapenems, which have the broadest spectrum of activity. This resistance mechan...
CDC7 kinase inhibitors: a survey of recent patent literature (2017-2022) [0.03%]
CDC7激酶抑制剂的专利回顾(2017-2022)
Takayuki Irie,Masaaki Sawa
Takayuki Irie
Introduction: CDC7 is a serine/threonine kinase which plays an important role in DNA replication. Inhibition of CDC7 in cancer cells causes lethal S phase or M phase progression, whereas inhibition of CDC7 in normal cells...